Physiological and Cognitive Biomarkers for Ketamine’s Antidepressant Effects

This single-group, open-label study administered a single 0.5 mg/kg intravenous ketamine infusion (over 40 minutes) to adults with treatment-resistant anxious or non-anxious major depressive disorder to identify physiological and cognitive biomarkers associated with ketamine’s rapid antidepressant effects.

Outcomes include physiological measures, cognitive testing, and symptom ratings to compare ketamine response between anxious and non-anxious subtypes; safety and tolerability were monitored through vitals, labs and ECG.